Sexually Transmitted Infections Treatment Guidelines, 2021
On July 10, 2025, King Pharmaceuticals, a subsidiary of Pfizer, issued a voluntary recall of specific referenced lots of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension). Further details and priority actions for health departments and healthcare providers are available from the Dear Colleague Letter.
On 1/16/2024, the FDA announced that they have exercised enforcement discretion for a temporary importation and use of Extencillin (benzathine benzylpenicillin injection, powder, for suspension). See more in this CDC letter. See more in this CDC letter. Temporary Importation of Lentocilin, (Benzathine Benzylpenicillin Tetrahydrate) Powder and diluent for suspension for injection, has also been allowed since July of 2024.
Bicillin L-A® is the first-line recommended treatment for syphilis and the only recommended treatment option for some patients.
CDC continues to monitor the situation and will post updates as needed.
CDC’s Sexually Transmitted Infections (STI) Treatment Guidelines, 2021 provides current evidence-based prevention, diagnostic and treatment recommendations that replace the 2015 guidance. The recommendations are intended to be a source for clinical guidance. Healthcare providers should always assess patients based on their clinical circumstances and local burden.
View the full STI Treatment Guidelines.
Access print-friendly versions of the wall chart, pocket guide, and guidelines.
Explore STD trainings, technical assistance, clinical consultation services, and more.
View tables of screening recommendations by disease or by population.
- Suspected Gonorrhea Treatment Failure Consultation Form
- Mycoplasma genitalium Treatment Failure Registry
- Customizable Announcement
- Screening Recommendations
- Tables of Evidence
- A Guide to Taking a Sexual History
- Expedited Partner Therapy
- Availability of STI Testing & Treatment Products
- Prenatal Syphilis Screening Laws
- National STD Curriculum